Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed James B. Bucher, JD as Chief Legal Officer and Corporate Secretary, effective September 18, 2025. Bucher brings over 30 years of life sciences legal experience, most recently serving as Chief Legal Officer at Harpoon Therapeutics where he led the company's acquisition by Merck in 2024.
He succeeds Andrea Paul, who served since 2022 and is departing to join an international law firm. Bucher's extensive experience includes corporate strategy, governance, capital raising, and M&A, having overseen more than $1 billion in capital raising at Exelixis and playing a key role in Alder Biopharmaceuticals' $2.4 billion acquisition by Lundbeck.
The appointment comes as Zentalis advances registration-intent clinical trials for azenosertib, their potentially first-in-class and best-in-class WEE1 inhibitor for ovarian cancer treatment.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported Q2 2025 financial results and provided updates on its clinical progress. The company's lead candidate azenosertib is advancing in the Phase 2 DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with topline data expected by year-end 2026.
The company maintains a strong financial position with $303.4 million in cash and equivalents, providing runway into late 2027. Operating expenses decreased to $36.1 million from $65.1 million year-over-year, reflecting the company's strategic restructuring announced in January 2025. R&D expenses decreased to $27.6 million from $48.4 million in the prior year.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a WEE1 inhibitor for ovarian cancer and other tumor types, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).
The company's Compensation Committee granted stock options to purchase 14,000 shares to one newly hired employee under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $1.19 per share, matching the closing price on the grant date. The options feature a 10-year term with four-year vesting, including 25% vesting after the first year and the remaining 75% vesting monthly over three years, contingent on continued employment.
Zentalis Pharmaceuticals (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company developing WEE1 inhibitor treatments for ovarian cancer and other tumors, has granted inducement stock options to a new employee. The Compensation Committee approved non-qualified stock options to purchase 14,000 shares of common stock under the company's 2022 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $1.45 per share, matching Zentalis' closing price on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.
Zentalis Pharmaceuticals (ZNTL) has initiated Part 2 of the Phase 2 DENALI clinical trial for azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). The trial consists of two parts: Part 2a aims to confirm optimal dosing with approximately 30 patients at each of two dose levels (400mg QD 5:2 and 300mg QD 5:2), while Part 2b will enroll about 70 additional patients at the selected dose.
Previous results from Part 1b showed promising outcomes with a 34.9% objective response rate and 6.3-month median duration of response in response-evaluable patients (n=43). The company expects topline data from DENALI Part 2 by year-end 2026, which could potentially support accelerated FDA approval. Zentalis estimates that approximately half of PROC patients overexpress Cyclin E1 protein, making them potential candidates for azenosertib treatment.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced the acceptance of an abstract for poster presentation at the 2025 ASCO Annual Meeting in Chicago from May 30 to June 3, 2025. The presentation will showcase clinical data from their ongoing Phase 1/2 trial of azenosertib, their WEE1 inhibitor, in combination with encorafenib and cetuximab for treating patients with metastatic BRAF V600E mutant colorectal cancer.
The poster presentation, titled 'Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib,' will be presented by Dr. Jeanne Tie on Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT. The data cutoff date for the presentation is April 4, 2025. The poster will be available on the Zentalis website under the 'Supporting Publications' tab in the 'Our Approach' section.
Zentalis Pharmaceuticals (ZNTL) has announced the granting of inducement stock options to three newly hired employees on April 1, 2025. The Compensation Committee approved non-qualified stock options to purchase 140,000 shares of common stock under the company's 2022 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $1.39 per share, matching the closing price of Zentalis' stock on The Nasdaq Global Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly installments over the following three years, subject to continued employment.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) reported significant progress in 2024 with its lead drug candidate azenosertib. The company presented promising clinical data for treating Cyclin E1+ platinum-resistant ovarian cancer (PROC), showing a 34.9% objective response rate and 6.3-month median duration of response in the DENALI Part 1b study.
Key developments include FDA Fast Track Designation for azenosertib and alignment on DENALI Part 2 study design, with topline data expected by year-end 2026. The company ended 2024 with $371.1 million in cash and equivalents, projecting runway into late 2027.
Financial results show R&D expenses decreased to $167.8 million from $189.6 million in 2023, while G&A expenses increased to $87.1 million from $64.4 million. A strategic restructuring announced in January 2025 aims to support late-stage clinical development of azenosertib.